Accession Number:

ADA446527

Title:

Aluminum-Containing Vaccine Associated Adverse Events: Role of Route of Administration and Gender

Descriptive Note:

Journal article

Corporate Author:

ARMY MEDICAL RESEARCH INST OF INFECTIOUS DISEASES FORT DETRICK MD

Personal Author(s):

Report Date:

2001-09-08

Pagination or Media Count:

4.0

Abstract:

Anthrax vaccine, adsorbed AVA is a vaccine containing aluminum hydroxide that is administered as six subcutaneous SQ doses over 18 months. It is the only aluminum hydroxide licensed for SQ administration. To optimize the vaccination schedule and route of administration, a prospective pilot study comparing the use of fewer doses administered intramuscularly IM as well as SQ with the licensed schedule and route was performed. Data from that study on injection site reactions were extracted for this repon. Erythema and induration occurred more commonly when the vaccine was administered SQ compared to IM P 0.0001, P 0.002, respectively. SQ nodules were found only among the SQ group P c 0.0001. Erythema, induration and SQ nodules were more common in women compared with men P c 0.001 after the first SQ dose of AVA dose. Reaction rates decreased when the interval between the first two doses of AVA was increased from 2 to 4 weeks.

Subject Categories:

  • Medicine and Medical Research
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE